The establishment of a new headquarters in a major US city like Boston signifies Akari Therapeutics' expansion and growth. The start of phase 3 clinical trials indicates progress in their product development, which could potentially lead to new product offerings and increased revenues in the future. This is likely to have a positive impact on the company's stock price in the short term.